Login to Your Account

Clinic Roundup

Wednesday, October 3, 2012

• Astex Pharmaceuticals Inc., of Dublin, Calif., said it started a Phase II study evaluating SGI-110, a small-molecule DNA-hypomethylating agent, in combination with carboplatin in platinum-resistant recurrent ovarian cancer patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription